The panel of outside advisers to the Food and Drug Administration voted unanimously to recommend a booster shot for seniors, as well as younger adults with other health problems, jobs or living situations that put them at increased risk from COVID-19.

The Food and Drug Administration said Thursday it will ask its outside experts to meet in late November to scrutinize Merck’s pill to treat COVID-19.

The Food and Drug Administration is wrestling with whether and when to offer another dose of the single-shot Johnson & Johnson COVID-19 vaccine, while a new study out Wednesday raises the prospect that using a different brand as the booster might work better.

With many Americans who got Pfizer vaccinations already rolling up their sleeves for a booster shot, millions of others who received the Moderna or Johnson & Johnson vaccine wait anxiously to learn when it's their turn.

If cleared by the Food and Drug Administration — a decision that could come in a matter of weeks — it would be the first pill shown to treat COVID-19. All other FDA-backed treatments against the disease require an IV or injection.

Drugmaker Merck said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus, potentially a leap forward in the global fight against the pandemic.

The Centers for Disease Control and Prevention on Thursday endorsed booster shots for millions of older or otherwise vulnerable Americans, opening a major new phase in the U.S vaccination drive against COVID-19.

The U.S. moved a step closer Wednesday to offering booster doses of Pfizer’s COVID-19 vaccine to senior citizens and others at high risk from the virus as the Food and Drug Administration signed off on the targeted use of extra shots.

Influential government advisers will debate Friday if there’s enough proof that a booster dose of Pfizer’s COVID-19 vaccine is safe and effective — the first step toward deciding which Americans need one and when.

The average person doesn’t need a COVID-19 booster yet, an international group of scientists — including two top U.S. regulators — wrote Monday in a scientific journal.

President Joe Biden says people who have been waiting for the FDA to formally approve a COVID-19 vaccine should get their shot now to stem what he calls a “pandemic of the unvaccinated.” Dr. Michael Angarone of Northwestern Medicine weighs in on that and more.

The U.S. gave full approval to Pfizer’s COVID-19 vaccine Monday, a milestone that could boost public confidence in the shots and spur more companies, universities and local governments to make vaccinations mandatory.

U.S. regulators on Monday added a new warning to Johnson & Johnson’s COVID-19 vaccine about links to a rare and potentially dangerous neurological reaction, but said it’s not entirely clear the shot caused the problem.

The acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual contacts between some of her agency’s drug reviewers and the maker of a controversial new Alzheimer’s drug.

As long-haulers grapple with lingering symptoms of COVID-19, some are turning to an antiparasitic for relief. We speak with local patients and experts about the use of ivermectin for treating COVID-19.

Dozens of different at-home COVID-19 tests are now available from big-box retailers and pharmacies. But before you run out and buy one, a few words of caution from Dr. Emily Landon, an infectious disease specialist at UChicago Medicine.